SHARE
COPY LINK

GLENCORE

Glencore warns of gloomy outlook

Swiss commodities giant Glencore says its performance in the third quarter was good, but cautioned that there is no sign that global conditions for its business would improve soon.

Glencore warns of gloomy outlook
Glencore CEO Ivan Glasenberg (Photo: International Students' Committee)

"Overall performance in (the third quarter) was good, despite generally weaker commodity prices," the company said in a statement on Thursday.

Although Glencore, based in Baar in the canton of Zug, did not publish any numbers for its third quarter, it reported solid growth during the quarter, especially in its metals and agricultural products units.

It also hailed the "robustness" in its marketing division, which is in charge of selling commodities on world markets.

Glencore said its industrial activities unit performance meanwhile "reflected lower prices, but nevertheless delivered a sequential and year-on-year overall volume improvement," with particularly strong growth in the energy products sector.

Its thermal coal production, for instance, nearly doubled to 33 million tonnes over the first nine months of its accounting year, while it pumped nearly 17 million barrels of oil during the same period.

Glencore did not say how its oil production compared to the same period a year ago.

In metals, Glencore's zinc production slipped 5.7 percent to 511.9 million tonnes during the first nine months, while copper production fell 16.3 percent to 394.2 million tonnes.

Nickel extraction meanwhile increased 16.1 percent to 25.8 million tonnes over the same period. over the same period.

Glencore also said its agricultural product production grew 11 percent to 5.5 million tonnes.

But the outlook going forward is far from rosy, the company said, pointing out that "we are not assuming any short term material improvement in global macro conditions".

However, the company, which has reserves of around $9.0 billion, said it was "confident that in this environment our business model places us in a strongly competitive position".

Glencore is preparing to merge with another Swiss commodities giant, Xstrata, after the two companies managed at the beginning of October to put aside the differences that had been blocking their union for months.

If the deal passes the final stumbling blocks, the massive new company would be worth $87 billion and capable of out-muscling most other giants in the field.

The two companies' general assemblies are set to meet on November 20 in Zug and should give their stamps of approval before the end of the year.

In order to receive a green light from regulatory authorities, Glencore may decide to exit some of its existing activities, the Financial Times reported.

Amid European Commission concern over the weight the merged company would have in the European zinc market, Glencore is considering backing out of a contract with Belgian-Swiss mining group Nyrstar, which is the world's biggest zinc producer, the British financial daily reported.

Glencore declined to comment on the report.

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

ZUG

Johnson and Johnson deny vaccine will be available privately in Switzerland

Johnson and Johnson have denied claims by Swiss public broadcaster SRF that the company's Janssen Vaccine would be available to private companies in Switzerland.

Johnson and Johnson deny vaccine will be available privately in Switzerland
Photo: AFP

The Covid-19 Vaccine Janssen, produced by American pharmaceutical company Johnson and Johnson, was approved by Swissmedic on Monday March 22nd.

However, as the government has declined to purchase the vaccine to incorporate it into its vaccine scheme, it is not expected to be publicly available.

On Tuesday, Switzerland’s public broadcaster SRF claimed the vaccine would however be available for private companies to vaccinate their employees.

Johnson and Johnson have denied this, saying their vaccine will not be made available to private entities. 

Here’s what you need to know.

Switzerland approves Johnson and Johnson – but will not purchase any doses

On Monday, the Swiss Agency for Therapeutic Products, Swissmedic, gave provisional approval for the vaccine manufactured by Johnson and Johnson (Covid-19 Vaccine Janssen).

This made it the third vaccine to be approved in Switzerland after the jabs from Moderna and Pfizer/BioNtech. Unfortunately however, this does not mean the vaccine will be available to the Swiss public anytime soon.

While Swissmedic has approved the vaccine for use in Switzerland, the Swiss government is yet to sign a vaccine supply contract with the manufacturer.

As The Local Switzerland reported yesterday, this is primarily because it would only be delivered in the summer “and that is too late for us”, said Nora Kronig, vice president of the Federal Office of Public Health (FOPH). 

READ MORE: Why Switzerland’s approval of the Johnson and Johnson jab will not speed up vaccinations

FOPH had previously announced the country aims to inoculate “everyone who wants it” by summer.

Kronig also said Switzerland is focusing on Pfizer / BioNtech and Moderna vaccines which use the so-called mRNA technology, “which is more effective, especially for vulnerable people”.

Johnson & Johnson vaccine uses a different technology.

Does this mean no Johnson and Johnson in Switzerland?

In a report on March 23rd Swiss public broadcaster SRF claimed any private entity wanting to import the vaccine can do so. 

“This means that a company in Switzerland, for example, can now buy this vaccine and have its staff vaccinated,” the media site claimed.

“At your own expense, but quickly and without any bureaucratic hurdles from the canton and federal government.”

However, ­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­­Thomas Moser, the Head of External Communications with Johnson and Johnson in Switzerland, told The Local Switzerland on Tuesday afternoon that the report was “incorrect” and as yet the vaccine would not be available to private entities. 

“In the current situation, J&J works exclusively with national and supranational authorities as well as international organisations such as COVAX to make our vaccine available,” he said, 

“This means that even with Swissmedic approval, direct orders will not be possible for the time being.”

As at Tuesday afternoon, the SRF report remained unchanged

Note: This article was changed on Tuesday afternoon to reflect the clarifications made by Johnson and Johnson directly to The Local Switzerland. 

SHOW COMMENTS